Page last updated: 2024-12-08

lysergamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lysergamide : An ergoline alkaloid comprising ergoline lacking hydrogens at positions 9 and 10 and also having a methyl group attached to the piperidine nitrogen. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID442072
CHEMBL ID227213
CHEBI ID4819
SCHEMBL ID183540
SCHEMBL ID11218830
MeSH IDM0066631

Synonyms (33)

Synonym
einecs 207-524-0
9,10-didehydro-6-methyl-ergoline-8-beta-carboxamide
dea no. 7310
ergoline-8-beta-carboxamide, 9,10-didehydro-6-methyl-
brn 0090708
C09160
478-94-4
ergine
lysergamide
PDSP2_001113
lysergic acid amide
9,10-didehydro-6-methylergoline-8beta-carboxamide
(+)-lysergamide
(8r)-9,10-didehydro-6-methylergoline-8-carboxamide
CHEBI:4819 ,
CHEMBL227213
4-25-00-00937 (beilstein handbook reference)
073830xh10 ,
unii-073830xh10
d-lyergic acid amide
(8.beta.)-9,10-didehydro-6-methylergoline-8-carboxamide
ergometrine maleate impurity c [ep impurity]
(8beta)-6-methyl-9,10-didehydroergoline-8-carboxamide
lysergamide [mi]
SCHEMBL183540
SCHEMBL11218830
AKOS030240648
ergine (lysergic acid amide)
DTXSID20893673
Q2041643
(6ar,9r)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(4r,7r)-6-methyl-6,11-diazatetracyclo[7.6.1.0?,?.0??,??]hexadeca-1(15),2,9,12(16),13-pentaene-4-carboxamide
(6ar,9r)-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However, the study could not be continued due to severe adverse effects in 3 of 4 subjects, such as cardiovascular dysregulation in two and a psychosis like state in one subject."( Variable adverse effects in subjects after ingestion of equal doses of Argyreia nervosa seeds.
Kremer, C; Paulke, A; Toennes, SW; Wunder, C, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ergoline alkaloidOne of a class of naturally occurring alkaloids with a structure based on that of ergoline.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
D(2) dopamine receptorRattus norvegicus (Norway rat)Kd0.00140.00030.81836.7000AID64790; AID64916; AID64918; AID64920; AID64925
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID291007Displacement of [3H]R-PIA from adenosine A1 receptor in lamb striatum membrane at 50 uM after 1 hr2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Novel ergopeptides as dual ligands for adenosine and dopamine receptors.
AID64920In vitro affinity at mutant D2 receptor (S197A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID64918In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID291005Displacement of [3H]SCH 23390 from dopamine D1 receptor in lamb striatum membrane at 50 uM after 1 hr2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Novel ergopeptides as dual ligands for adenosine and dopamine receptors.
AID64925In vitro affinity at wild type Dopamine receptor D2 on C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID291006Displacement of [3H]YM 09151-2 from dopamine D2 receptor in lamb striatum membrane at 50 uM after 2 hrs2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Novel ergopeptides as dual ligands for adenosine and dopamine receptors.
AID291008Displacement of [3H]CGS 21680 from adenosine A2A receptor in lamb striatum membrane at 50 uM after 2 hrs2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
Novel ergopeptides as dual ligands for adenosine and dopamine receptors.
AID64916In vitro affinity at mutant D2 receptor (S193A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID64790In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (25.81)18.7374
1990's2 (6.45)18.2507
2000's4 (12.90)29.6817
2010's10 (32.26)24.3611
2020's7 (22.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.26 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index65.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.88%)6.00%
Case Studies3 (8.82%)4.05%
Observational0 (0.00%)0.25%
Other29 (85.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]